ENVVENO MEDICAL CORP
NVNONASDAQTrading Snapshot
- Day Range
- $5.22 โ $5.76
- 52-Week Range
- $5.22 โ $14.89
- Volume (shares)
- 10,355
- Avg Volume (shares)
- โ
- Shares Outstanding
- 694,826
- Next Earnings
- 2027-03-25
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-22.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- โ1.1%
ENVVENO MEDICAL CORP
NVNOAbout ENVVENO MEDICAL CORP
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVeยฎ System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal study An estimated 3 million pati

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from th

enVVeno Medicalย Participates in the Virtual Investor 'Why Now' On-Demand Conference
Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer